Acute Bronchitis

LONDON, Oct. 9, 2023 /PRNewswire/ -- Bronchitis is a common respiratory illness mainly caused by viral or bacterial infection. As per an epidemiology study conducted recently by the NIH, 5% of the global population reports an episode of acute bronchitis every year. This indicated to an ever-increasing disease burden that needs to be managed efficiently. Bronchitis is an inflammatory disorder that predominantly affects the airways responsible for carrying air to the lungs, i.e., the bronchial tubes. In this condition, these tubes become irritated and swollen, leading to various symptoms that can range from mild to severe. There are two primary types of bronchitis, i.e., acute brnature andich is temporary in nature and chronic bronchitis which is more persistent and serious. Price and Market Access Medical researchers, pharmaceuticals, and other related healthcare bodies are involved in continuous R&D activities with an aim to transform the diagnostic and treatment dynamics of this disease. In this journey, many of them seek healthcare consulting services from DLI to get complete disease overview, market intelligence, along with drug development and clinical trial management-based assistance. It also helps them with clinical trial feasibility analysis, commercial strategy analysis, product portfolio extension, price reimbursement, and drug launch strategies. Elucidating the causes and symptoms: The major factors triggering this ailment are viral and bacterial infections, exposure to environmental irritants, smoking, gastroesophageal reflux disease, certain allergies, immunodeficiency, and inhalation of harmful chemicals. Many people ask that is bronchitis contagious in nature? Well, it can be contagious when it is caused due to the action of a virus or bacteria. Discover More About Pricing and Reimbursement, Epidemiology Study, and Healthcare @ Bronchitis chest pain, cough, sore throat, mild fever, shortness of breath, breathing issues, and fatigue among others are common symptoms of this ailment. Talking of bronchitis vs pneumonia, the latter is far more severe and has higher potential for complications. Diagnosis and treatment: To diagnose bronchitis, a healthcare provider typically conducts a thorough medical history and physical examination, focusing on respiratory symptoms. Diagnostic tests such as chest X-rays, pulmonary function test or sputum cultures may be ordered in certain cases to rule out other conditions or confirm a bacterial infection. Treatment for bronchitis varies based on its type and underlying cause. For acute bronchitis, which is often viral, supportive care such as rest, hydration, and over-the-counter bronchitis medications including bronchitis cough syrup may be recommended. In cases of bacterial bronchitis, antibiotics may be prescribed. Chronic bronchitis management involves lifestyle changes like smoking cessation and avoiding irritants, along with medications like bronchodilators and inhaled corticosteroids to manage symptoms and prevent exacerbations. Following certain home remedies for bronchitis also helps. Apart from that, proper bronchitis diet constituting of healthy and natural food items may also result in bronchitis relief. Unlock the Benefits Today! Get Started Now and Elevate Your Experience @ Checkout_Bronchitis (brong-KY-tis) Summing Up: Bronchitis is known to impact a significant portion of the global population. This respiratory infection is characterized by inflammation of the bronchial tubes, which can result from viral or bacterial infections, as well as exposure to irritants like smoke or pollutants. Acute bronchitis typically presents with a persistent cough, while chronic bronchitis involves a chronic cough with increased mucus production. DLI has been assisting industry participants in early detection and monitoring of bronchitis and related respiratory conditions. By offering a deep understanding of disease patterns and treatment options, DLI consultants contribute to personalized care plans for patients in the long run. By leveraging DLI's pharma consulting services, players can easily formulate ideal market access strategies along with post launch services with ease. Browse Through More Environmental Diseases Research Reports. Related Reports: Addressing Ethical Considerations: Insights & Strategies: Investigating AI's Potential to Transform Radiology: Applications AI in Medical Imagingm Addressing Ethical Considerations: Insights & Strategies for AI in Healthcare Top cancer-related causes of death Paxlovid is recognized as a COVID-19 Breakthrough Therapy with Emergency Use Authorization. The Top 5 Monkeypox Research Companies and Monkeypox How Technology is Revolutionizing the Drug Discovery Industry Treatment, Research, and Leading Companies dealing with lung cancer Money Is Important: Boosting Clinical Trial Revenue Strategies by Resolving CRO Issues Dry Eye Disease Is Miebo Treating Qalsody: A Ground-Breaking Medicine from Biogen Inc. How Can Clinical Trial Ancillary Management Be Improved to Enhance Research Outcomes? A Brief History of the Monkeypox Disease Global Market: Taking Advantage of Possibilities for a Healthier Future and Surmounting Obstacles by Providing Hope for Lupus Disease Research Overcoming Obstacles by Presenting Hope in Lupus Disease Research Diabetes Treatment Without Needles: Diagnostic Advances and Market Change Manufacturing Barriers for Early Pancreatic Cancer Detection Kit Manufacturers: Understanding the Maze Creating the Future of Pneumonia Treatment Options is boosting market growth. A Game-Changer for the Management of Patients with Ovarian Cancer: Inhibitors of PARP Managing the Alzheimer's Landscape: How We Direct Market Participants to Unique Solutions Healthcare is being revolutionized by AI-driven Personalized Medicine. New Topical Drug Delivery Therapies Unlock the Future of Skin-Credible Care, Causing a Psoriasis Care Crisis! About Disease Landscape:  Disease Landscape, a pioneering company specializing in Disease Intelligence, Pricing, and Market Access. Utilizing the power of data analytics, Disease Landscape Insights is dedicated to healthcare sector with invaluable, finely crafted insights and recommendations regarding global pricing and market access strategies. As a specialized firm, we are committed to delivering unparalleled insights into pricing and market access, custom-tailored to the healthcare and pharmaceutical industries. Our data-driven solutions and cutting-edge technology position us as your trustworthy partner, offering swift, adaptable, and evidence-based alternatives to traditional market access and pricing research methods.  Our core competencies encompass Market Research Services, Consulting Services, Global Pricing and Market Access, Epidemiology Studies, as well as Product Portfolio and Pipeline Services. Our expertise lies in furnishing comprehensive data intelligence throughout every phase of drug and device research.  Contact Us:  Disease Landscape Insights LLP  6th Floor, Sr No.207, Office A H 6070 Phase 1  Solitaire Business Hub, Viman Nagar  Pune, Maharashtra, 411014  Email: [email protected] Email: [email protected] Sales: +44-2038074155  Asia Office: +917447409162 Blog:   Case Study:    Pharma consulting Services  Follow Us: LinkedIn | Twitter | Facebook Logo: SOURCE Disease Landscape Insights

Voriconazole Inhalation Powder (TFF VORI) is an investigational, inhaled formulation of voriconazole developed using TFF Pharmaceuticals Thin Film Freezing technology that is currently being evaluated in a Phase 2 trial for the treatment of invasive pulmonary Aspergillosis (IPA). TFF VORI is not currently authorized or approved in any country.The Expanded Access Program covers pulmonary aspergillosis including invasive pulmonary aspergillosis, chronic pulmonary aspergillosis, allergic bronchopulmonary aspergillosis, aspergillus tracheobronchitis, and aspergillus bronchoanastomotic infections as well as other voriconazole responsive fungal pulmonary infections.Uniphar Durbin Ireland Limited has been appointed to implement TFF Pharmaceutical’s Expanded Access Program in the United States, Australia, United Kingdom, Canada, and within select countries in Europe. DUBLIN, Ireland and FORT WORTH, Texas, July 31, 2023 (GLOBE NEWSWIRE) -- Uniphar Durbin Ireland Limited (“Durbin” or the “Company”), a part of Uniphar Group’s Product Access Division and a leading specialist in the international distribution of specialized pharmaceuticals, and TFF Pharmaceuticals, Inc. (Nasdaq: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced the opening of an Expanded Access Program (EAP) enabling patients access to TFF-VORI in the United States, Australia, United Kingdom, Canada and select countries in Europe. “We are pleased to be working with Durbin to offer the Expanded Access Program for TFF VORI,” said Dr. Harlan Weisman, Chief Executive Officer of TFF Pharmaceuticals. “Durbin has an accomplished track record of successfully executing Expanded Access Programs for some of the most well recognized companies in the pharmaceutical industry, and through this partnership, we expect many patients will have the opportunity to gain early access to TFF VORI. The EAP comes after positive clinical outcomes in two patients with pulmonary fungal infection treated with TFF VORI on a compassionate use basis. The EAP is meant to provide access to TFF VORI in patients who are not eligible for our ongoing clinical trial and who have limited or no other treatment options or who have had unfavorable response to adequate standard of care therapy including to oral or intravenous voriconazole.” Dan Piggott, Managing Director of Uniphar Group’s Product Access Division stated, “We are very pleased to work with TFF to provide early access to TFF VORI to patients with pulmonary aspergillosis and other devastating voriconazole responsive fungal pulmonary infections. In the months ahead, we look forward to expanding this program across multiple countries so that this therapy can be offered to a patient population with few or no treatment options.” About TFF VORI: TFF VORI is a next-generation, direct-to-lung, inhaled dry powder formulation of voriconazole in development for the treatment pulmonary fungal infections including pulmonary aspergillosis. TFF VORI is currently under investigation in an ongoing Phase 2 study for the treatment of IPA. Voriconazole is recommended as the first-line treatment for IPA, but in its oral form is associated with significant drug-drug interactions and toxicities. Direct-to-lung delivery is predicted to increase local lung concentrations with diminished systemic exposures to improve the therapeutic index of voriconazole. The therapy can be delivered via a dry powder inhaler to enable ease of administration directly to the lung. About TFF Pharmaceuticals: TFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company using patented thin film freezing technology to develop and transform medicines into dry powder formulations for better efficacy, safety, and stability. The company’s versatile Thin Film Freezing technology platform has broad applicability with the potential to convert many drugs, including vaccines, small and large molecules, and biologics, into an elegant dry powder formulation, highly advantageous for inhalation. TFF has two lead drug candidates in the clinic: TFF VORI (Voriconazole Inhalation Powder) and TFF TAC (Tacrolimus Inhalation Powder). The Company continues collaborations with a broad array of pharmaceutical companies, academic institutions, and government partners to revolutionize healthcare around the globe. The TFF Platform is protected by 120+ patents issued or pending in the U.S. and internationally. To learn more about TFF Pharmaceuticals and its product candidates, visit the Company’s website at https://tffpharma.com. About Durbin: Uniphar Durbin Ireland Limited, a Uniphar company, is a global, specialist pharmaceutical services and products company who partner with pharmaceutical and biotech companies to provide ethical access to medicines for patients with unmet medical needs. A part of Uniphar Group’s Product Access Division, Durbin works in partnership with global pharmaceutical and biotech companies to provide Expanded Access Programs (EAPs), including Named Patient Supply and Cohort Programs. The company has over 25 years’ experience designing and implementing EAPs and specializes in strategic consultancy, asset specific program design and innovative, customized delivery models. SAFE HARBOR: This press release contains forward-looking statements regarding TFF Pharmaceuticals, Inc., including, the benefits of the Company’s TFF platform and the Company’s plans to add to its existing pipeline of product candidates. Those forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially. Among those factors are: (i) the risk that the Company may not be able to successfully roll-out its Early Access Program for TFF VORI or, if it can, achieve the expected benefits of the Early Access Program, (ii) the risk that the Company may not be able to successfully conclude clinical testing or obtain pre-market approval of TFF VORI or any of its other dry powder product candidates, (iii) success in the Early Access Program or early phases of pre-clinical and clinical trials does not ensure that later clinical trials will be successful, and interim results of a clinical trial do not necessarily predict final results, (iv) no drug product incorporating the TFF platform has received FDA pre-market approval or otherwise been incorporated into a commercial drug product, (v) the Company has no current agreements or understandings with any large pharmaceutical companies for the development of a drug product incorporating the TFF Platform, (vi) the risk that the Company will not be able to conclude a long-term commercial agreement with any third-party, and (vi) those other risks disclosed in the section “Risk Factors” included in the Company’s Quarterly Report on Form 10-Q filed with the SEC on May 11, 2023. TFF Pharmaceuticals cautions readers not to place undue reliance on any forward-looking statements. TFF Pharmaceuticals does not undertake, and specifically disclaims, any obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur, except as required by law. Durbin Contact: Mark Haxton Uniphar Durbin Ireland LimitedM.Haxton@durbinglobal.com TFFVORI@durbinglobal.com Investor Relations Contact:Corey Davis, Ph.D. LifeSci Advisors (212) 915-2577cdavis@lifesciadvisors.com

South Korea's Ministry of Health and Welfare has released its report on the conduct of temporary telemedicine during the height of the COVID-19 pandemic. FINDINGS According to the report, over 25,000 medical institutions provided remote treatment to 13.79 million people from February 2020 to January 2023. Of the 36.61 million treatments administered via telehealth, most treatments (29.25 million) were home treatments for COVID-19 cases while about 1.36 million treatment cases were first-time visits and 5.14 million cases received prescriptions following consultations. The report pointed out that most telemedicine services were conducted by neighbourhood clinics (accounting for 93.6% of all participating healthcare providers and 86.2% of all recorded treatments). Large hospitals previously aired their concerns about shouldering most of the telemedicine demand but this had not been the case at all, the MOHW noted. Moreover, the report found that there was a high telemedicine uptake among the elderly and those with chronic diseases. Most telehealth treatments, or about 2.88 million treatments, had been provided to senior folks aged 60 and above. Telemedicine had been administered mostly for patients with hypertension, acute bronchitis, and diabetes. Additionally, there had been increased adherence to prescription medicines among patients with chronic diseases following the temporary implementation of telemedicine in 2020. "Through this study, it was confirmed that non-face-to-face treatment can contribute to some extent in improving health, such as improving the continuity of prescriptions for the elderly," the MOHW said. WHY IT MATTERS To recall, the South Korean government temporarily permitted the conduct of telemedicine in February 2020 as a means to restrict mobility and stem the spread of COVID-19 infections. Following positive outcomes, the MOHW now calls to institutionalise telemedicine by revising related provisions in the country's Medical Service Act. Meanwhile, the government recently recognised the Korean Medical Association's proposal to make telemedicine a permanent supplement to face-to-face healthcare services. THE LARGER TREND The MOHW also shared from the 2020 survey by the National Health Insurance Service that most patients who have received prescriptions over the phone said they are willing to use the service again in the future. Being safe from contracting infectious diseases and the reduced waiting time were cited as reasons to continue using telemedicine. A similar satisfaction survey done by the Korea Health Industry Development Institute in October also noted the same willingness to continue seeking prescriptions over the phone. ON THE RECORD "We were able to confirm the effectiveness and safety of non-face-to-face treatment and we were able to allay concerns about high concentrated demand for telemedicine among large hospitals," Second Vice Minister of Health and Welfare Park Min-soo said. "In the conduct of telemedicine, patients’ right to choose and access to medical care, as well as the professionalism of medical personnel, are respected. We have plans to allow the use of supplementary devices so that both patients and medical personnel can use telemedicine safely," he added.